1. Home
  2. DNA vs EMBC Comparison

DNA vs EMBC Comparison

Compare DNA & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNA
  • EMBC
  • Stock Information
  • Founded
  • DNA 2008
  • EMBC 1924
  • Country
  • DNA United States
  • EMBC United States
  • Employees
  • DNA 834
  • EMBC N/A
  • Industry
  • DNA Biotechnology: Biological Products (No Diagnostic Substances)
  • EMBC Medical/Dental Instruments
  • Sector
  • DNA Health Care
  • EMBC Health Care
  • Exchange
  • DNA Nasdaq
  • EMBC Nasdaq
  • Market Cap
  • DNA 731.1M
  • EMBC 788.4M
  • IPO Year
  • DNA N/A
  • EMBC N/A
  • Fundamental
  • Price
  • DNA $12.42
  • EMBC $14.49
  • Analyst Decision
  • DNA Hold
  • EMBC Buy
  • Analyst Count
  • DNA 2
  • EMBC 2
  • Target Price
  • DNA $9.50
  • EMBC $19.00
  • AVG Volume (30 Days)
  • DNA 1.6M
  • EMBC 689.7K
  • Earning Date
  • DNA 08-07-2025
  • EMBC 08-08-2025
  • Dividend Yield
  • DNA N/A
  • EMBC 4.14%
  • EPS Growth
  • DNA N/A
  • EMBC 18.26
  • EPS
  • DNA N/A
  • EMBC 1.42
  • Revenue
  • DNA $230,815,000.00
  • EMBC $1,102,500,000.00
  • Revenue This Year
  • DNA N/A
  • EMBC N/A
  • Revenue Next Year
  • DNA $13.73
  • EMBC N/A
  • P/E Ratio
  • DNA N/A
  • EMBC $10.20
  • Revenue Growth
  • DNA 25.21
  • EMBC N/A
  • 52 Week Low
  • DNA $5.00
  • EMBC $9.20
  • 52 Week High
  • DNA $16.85
  • EMBC $21.48
  • Technical
  • Relative Strength Index (RSI)
  • DNA 49.28
  • EMBC 70.84
  • Support Level
  • DNA $11.92
  • EMBC $13.85
  • Resistance Level
  • DNA $12.81
  • EMBC $14.69
  • Average True Range (ATR)
  • DNA 0.99
  • EMBC 0.52
  • MACD
  • DNA -0.13
  • EMBC 0.06
  • Stochastic Oscillator
  • DNA 38.37
  • EMBC 81.37

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: